---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124558"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:05:27.357824+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TScan Q3 net loss $29.9M; ALLOHA heme trial shows no relapses in 16 treatment patients

## Summary
- Net loss $29.9M in Q3 2024 vs $23.0M in Q3 2023; revenue $1.0M vs $3.9M.
- Cash $271.1M, excluding $5M restricted cash; funding operations into Q4 2026.
- ALLOHA Phase 1 heme trial: 16/16 treatment-arm patients relapse-free and MRD-negative as of July 8 cutoff; 3/11 control-arm relapses.
- On track to dose first patient with multiplex TCR-T therapy and provide Phase 1 update by end of 2024.
- IND filing for MAGE-A4-targeted TCR-T (TSC-202-A0201) planned by end of year.

## SEC filing metadata
- accession: 0000950170-24-124558
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017024124558/0000950170-24-124558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017024124558/tcrx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124558
- JSON: https://secwatch.observer/filing/0000950170-24-124558.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.